IOCL donates equipment worth ₹22 crore SVIMS
The advanced MRI and CT scanners were virtually inaugurated on Thursday (July 17) by Union Minister for Oil and Natural Gas Hardeep Singh Puri, while the event was physically attended by TTD trust board Chairman B.R. Naidu, TUDA chairman C. Divakar Reddy, SVIMS Director and Vice-Chancellor R.V. Kumar among others.
Acknowledging IOCL's gesture, Mr. Naidu said that the SVIMS would soon become the best super specialty hospital in the entire country with the support of such benefactors. He explained the steps taken up by the TTD management, including donating ₹140 crore every year, to ensure best medical treatment to the poor.
The 3TESLA MRI scanner and 4D CT simulator system (used for radiotherapy) would be used to screen tumours in cancer patients without any side effects. The equipment would help the hospital diagnose 2.5 lakh poor patients at a nominal charge every year.
IOCL Marketing Director Satish Kumar appreciated SVIMS for reaching out to the poor patients and offered to support its future endeavours. SVIMS Director Dr. R.V. Kumar said that the hospital provided medical education exclusively to girl students by running Sri Padmavathi Medical College for Women.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
6 hours ago
- The Hindu
Tripura Governor hails medical advancement
Tripura Governor N. Indrasena Reddy has hailed the medical fraternity for embracing modern technology to get medical advancement to the reach of common man. Speaking at a golden jubilee international conference organised by Sri Venkateswara Medical College Alumni Association (SVMCAA) here on Friday, the Governor recalled that it was during the Covid-19 pandemic that the technology had come to the fore. 'As technology advances, we need to keep abreast of the same and the syllabus we studied decades back has to be thoroughly revised to meet the current day needs,' he said. Tirupati District Collector S. Venkateswar saw a greater need for the alumni networks not only in promoting their alma mater, but also in conducting conferences to let the information on medical advancement percolate to all levels. MLC Cipai Subramanyam, TTD board member G. Bhanuprakash Reddy, SVMCAA Chairperson Rayapu Ramesh Babu, SVMC Principal G. Ravi Prabhu, Ruia Hospital Superintendent R. Radha and Government Maternity Hospital Superintendent K. Parthasarathy took part.
The Hindu
6 hours ago
- The Hindu
‘CSIR's role in spearheading research will help India compete with developed nations'
The Council of Scientific & Industrial Research's (CSIR) role in spearheading research in various fields would enable the country to compete with other developed countries, said N. Kalaiselvi, Director General, CSIR, and Secretary, Department of Scientific and Industrial Research, New Delhi. Participating in the 78th foundation day of CSIR-Central Electrochemical Research Institute (CSIR-CECRI) and inauguration of Sir C.V. Raman Research Scholars' Hostel and CO2-adsorbent pilot plant facility here on Friday, she advised research scholars to align their research towards technology and urged scientists to work towards CSIR@100 and Viksit Bharat 2047 goals. 'Our country is growing exponentially as the world's largest economy and to realise this remarkable goal, we all should dedicate ourselves to the development of the nation,' she said, adding the institution was working towards growth in fields such as food, water, sanitation, security, and energy. 'In the field of health, sickle cell anaemia among tribals is rampant. As it is particularly prevalent among tribals in Chhattisgarh, Odisha, and Maharashtra, we have started the research towards curing that,' she added. As the research to remove oxygen-deficient cells which play a major role in the disease was being done for more than eight years, the first step in identification using a simplified technique was developed now, Ms. Kalaiselvi said. The PCR test, through which the disease could be identified in 20 minutes, would soon be made available on a government e-marketplace platform, she noted. The research in genome sequencing and editing to remove the affected gene, if done successfully, could be done at ₹1 crore in India whereas the treatment would cost around ₹28 crore in the USA, Ms. Kalaiselvi said. The main aim of the research was to reduce the treatment cost to ₹50 lakh to cover it under Prime Minister's Health Insurance Scheme, she added. The CSIR's initiative to support fisherwomen in Rameswaram by providing them seaweed had made them economically independent. The research being done by the team to see if the seaweed growth could happen in controlled waterbody condition in houses and farms, it could further empower the women, the CSIR DG said. She urged the researchers to innovate more and translate their ideas into entrepreneurships, startups, MSMEs, etc., as their products contributed around 40% of India's total exports. Alok Sharma, Director (R&D), IOCL, assured continued support of IOCL to the CSIR-CECRI and solicited collaboration of all CSIR Labs, especially CSIR-CECRI, in energy generation and storage.
Hindustan Times
8 hours ago
- Hindustan Times
Why access to stem cell transplants is out of reach for many thalassemia patients in India
India carries the world's most significant burden of thalassemia, with an estimated 150,000 patients and 12,000 new cases every year. While medical science continues to advance and success rates after hematopoietic stem cell transplants (HSCT) have increased globally as a potential cure for thalassemia, far too many Indian families still lack access to this life-saving treatment. The barriers are not just medical, but they are deeply rooted in systemic inequities, beginning with the first step—Human Leukocyte Antigen (HLA). Thalassemia HLAs are proteins on the surface of cells that play a crucial role in the body's immune system. They act like identification tags, allowing the immune system to distinguish between the body's cells and foreign invaders, such as bacteria or viruses. Managing thalassemia requires lifelong care that puts patient and their family into an immense financial hardship. Patients undergo regular blood transfusions and iron chelation therapy. India is the thalassemia capital of the world, with a thalassemia burden of around 150,000 patients and an incidence of approximately 12,000 every year. The recurring cost of ongoing optimal patient management varies between ₹100,000 and ₹120,000 per year. This is not affordable for most Indian families, as the estimated per capita Net National Income (NNI) of India is ₹126,000 ($ 1732). The permanent curative treatment option of HSCT is not well known in India. However, current experience worldwide indicates that more than 90% of patients now survive HSCT, and disease-free survival rates are around 80%. A significant challenge to accessing blood stem cell transplant is the associated costs, as most of the payment for HSCT is out of pocket. The Indian government is supporting ongoing patient needs through a national-level blood safety policy and the institutionalisation of state-level blood availability for patients' monthly blood transfusions and iron chelation medicines. It is also encouraging the public and private sectors to support transplant costs for poor patients as Corporate Social Responsibility (CSR) initiatives. Some states have state-level schemes to help patients with thalassemia and HSCT expenses. Thus, eligible poor patients opting for an HSCT can avail themselves of funding support from Government schemes, CSR funds, and other donations. However, these funds do not cover the costs of high-resolution HLA typing, which is the initial step in the medical assessment for an HSCT. Several global and national non-profit organisations—working towards giving patients suffering from thalassemia a second chance at life—have launched initiatives to address this gap. The initiatives include free or subsidised high-re HLA typing for families from low-income backgrounds. Such programmes are designed to enable transplant centres, NGOs, and hospitals to work in close collaboration across India. Through these initiatives, tools such as awareness drives and campaigns have also been conducted in urban and semi-urban areas to educate families about the potential cure and facilitate early intervention. These efforts have led to thousands of families receiving free HLA typing, and in numerous--instances, access to donor searches through worldwide stem cell registries when no familial match was found. We have also adopted collaborative models that not only assist Indian patients but also extend support to neighbouring countries, such as Sri Lanka, Bangladesh, and the Maldives, demonstrating the regional need for cross-border medical cooperation. Despite this advancement, large-scale systemic difficulties persist. Transplants are resource-intensive procedures that necessitate robust infrastructure, a diverse donor registry pool, donor availability, and post-transplant care. All of which demand significant public health investment. Without the wide-ranging inclusion of diagnostic tools, such as high-res HLA typing and blood stem cell transplants, in government-funded healthcare plans, treatment remains a luxury for the few rather than a right for all. The cost of a match should not be borne only by the patient or their family. It must be viewed as a shared responsibility across sectors, including government, healthcare institutions, civil society, and corporate partners alike. Only then can equitable access to curative options and care become a grounded reality for every child born with thalassemia, regardless of their socio-economic background. This article is authored by Dr Nitin Agarwal, MD, Transfusion Medicine, HOD-Donor Request Management, DKMS Foundation India.
